Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Incyte pays $45mm up front for rights to Calithera's arginase inhibitor

Executive Summary

Incyte Corp. licensed global rights to develop and sell Calithera Biosciences Inc.’s arginase inhibitor CB1158 in hematology and oncology indications. Incyte paid $45mm up front and made an $8mm equity investment through the purchase of 1.7mm Calithera common shares at $4.65 (a slight premium).

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies